Postmarket Study Published on Elixir Medical's DESolve Bioresorbable Scaffold
November 27, 2018—Twelve-month results from the multicenter postmarket clinical follow-up study of the DESolve novolimus‐eluting bioresorbable coronary scaffold system (Elixir Medical Corporation) were published by Holger Nef, MD, et al in Catheterization and Cardiovascular Interventions (2018;92:1021–1027). The investigators concluded that the DESolve bioresorbable scaffold (BRS) is a safe and effective treatment for coronary lesions in patients with stable coronary artery disease.
According to the investigators, the DESolve BRS combines a poly‐L‐lactide–based backbone with a biodegradable polylactide‐based polymer and novolimus, a macrocyclic lactone mTOR inhibitor.
The study enrolled 102 patients (mean age, 62 years; 77.5% men) at 10 European sites. Investigators performed a comparison of baseline and postprocedural angiographic assessments. Additionally, they examined a device‐oriented composite endpoint (cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization) and rate of scaffold thrombosis at 12 months.
As reported in Catheterization and Cardiovascular Interventions, the device was successfully delivered and deployed in 98.2% (107/109) of the lesions, with two failures to cross the lesion. A total of 100 patients (109 lesions) were treated with the DESolve BRS. Postprocedural angiographic assessment indicated an in‐scaffold acute gain of 1.54 ± 0.44 mm, with a reduction in percent diameter stenosis from 61.00% ± 11.29% to 12.69% ± 0.44%.
At 12 months, the device‐oriented composite endpoint had occurred in 3% (3/100) of patients, with 1% (1/100) experiencing scaffold thrombosis and myocardial infarction and 3% (3/100) undergoing target lesion revascularization. There were no cardiac deaths.
Larger long‐term prospective studies are needed, advised the investigators in Catheterization and Cardiovascular Interventions.
advertisement
Featured Video
Patients have to trust that if I were in their shoes, I wouldn’t do anything differently.
Sponsored by Boston Scientific
Related Articles
CASE REPORT: Railway™ Sheathless Guide System
The initial experience using novel sheathless technology to facilitate optimal radial access.
By Srini Potluri, MD
EluNIR™ Coronary Stent System: From Design to Practice
The inventor's perspective on the manufacturing process and enhanced features of the EluNIR™ device and the intended effects on performance and outcomes.
With Yoram Richter, PhD
Overcoming Radial Access Challenges
Case reports with commentary describing techniques for managing tortuosity during PCI for coronary artery disease.
With John C. Wang, MD, MSc; and Kevin J. Croce, MD, PhD
Railway™: The Future of Radial Access
An inventor’s perspective on using the Railway™ device to overcome even the most challenging cases.
By Kintur Sanghvi, MD, FACC, FSCAI
Top 5 Articles From October 2018
CT Assessment Before TMVR
By Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCT
Panel: Mayra Guerrero, MD; and Marco Barbanti, MD
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Complicated Radial Access During Primary PCI
By Moderator: Pieter C. Smits, MD, PhD, FESC
Panel: Mohamed Abdel-Wahab, MD, FESC; Peter W. Danse, MD; and Valeria Paradies, MD
Peripheral Vascular Programs Could Improve Population Health and Grow Volumes
An overview of the steps involved in developing a PAD program to address this underserved patient population.
By Ginger Biesbrock, PA-C, MPH, MPAS, AACC; and Joel Sauer, MBA
Planning for Transcatheter Aortic Valve Replacement
By Moderator: Mauricio G. Cohen, MD, FACC, FSCAI
Panel: Santiago Garcia, MD, FACC, FSCAI; William O’Neill, MD; and Molly Szerlip, MD, FACC, FSCAI
Top 5 from EVToday's Current Issue
Designing a Versatile Procedural Environment for a Rapidly Changing Interventional Field
A dyad perspective on building an advanced endovascular suite.
With Barry T. Katzen, MD
Ask the Experts: What Is the Biggest Unanswered Question in Ischemic Stroke Care?
Experts discuss who shouldn’t be treated, improving center-to-center communication, triaging patients to the right center for care, and reigning in estimates on large vessel occlusions appropriate for treatment.
With Blaise Baxter, MD; Ronil V. Chandra, MBBS, MMed, FRANZCR, CCINR; Mayank Goyal, MD, FRCPC, FAHA, FCAHS; and Ansaar T. Rai, MD, MBA
Tips & Tricks: Crossing Acute Large Vessel Occlusions
A review of available study data with an emphasis on what data are still needed.
